ORLANDO—Intermittent and continuous androgen suppression are associated with similar overall survival outcomes in men who have PSA progression after radiotherapy for prostate cancer (PCa), according to new data.
ORLANDO—An investigational drug called abiraterone acetate may improve the chances of survival among men with metastatic castration-resistant prostate cancer (CRPC) whose disease is progressing after receiving docetaxel-based chemotherapy, according to new findings.
ORLANDO—Radiographic imaging studies often are used inappropriately for men with newly diagnosed prostate cancer (PCa), with certain patients undergoing unnecessary imaging and others not receiving imaging even though it is recommended, researchers concluded.
ORLANDO—A pomegranate extract slowed progression of prostate cancer (PCa) in a study of men who had rising PSA levels after primary treatment for the malignancy.
Use of recombinant tissue plasminogen activator (rt-PA) instead of heparin once weekly as a locking solution for central venous catheters in hemodialysis (HD) patients significantly decreases the risk of catheter malfunction and bacteremia compared with using heparin three times a week, according to Canadian researchers.